- Home
- MIST vs CYBN Comparison
MIST vs CYBN Comparison
Compare MIST & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CYBN
- Stock Information
- Founded
- MIST 2003
- CYBN 2019
- Country
- MIST Canada
- CYBN Canada
- Employees
- MIST N/A
- CYBN N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CYBN Pharmaceuticals and Biotechnology
- Sector
- MIST Health Care
- CYBN Health Care
- Exchange
- MIST Nasdaq
- CYBN Nasdaq
- Market Cap
- MIST 163.2M
- CYBN 147.4M
- IPO Year
- MIST N/A
- CYBN N/A
- Fundamental
- Price
- MIST $1.80
- CYBN $5.95
- Analyst Decision
- MIST Strong Buy
- CYBN Strong Buy
- Analyst Count
- MIST 3
- CYBN 3
- Target Price
- MIST $6.33
- CYBN $85.00
- AVG Volume (30 Days)
- MIST 1.4M
- CYBN 1.1M
- Earning Date
- MIST 11-11-2025
- CYBN 11-17-2025
- Dividend Yield
- MIST N/A
- CYBN N/A
- EPS Growth
- MIST N/A
- CYBN N/A
- EPS
- MIST N/A
- CYBN N/A
- Revenue
- MIST N/A
- CYBN N/A
- Revenue This Year
- MIST N/A
- CYBN N/A
- Revenue Next Year
- MIST N/A
- CYBN N/A
- P/E Ratio
- MIST N/A
- CYBN N/A
- Revenue Growth
- MIST N/A
- CYBN N/A
- 52 Week Low
- MIST $0.63
- CYBN $4.81
- 52 Week High
- MIST $2.75
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- MIST 40.52
- CYBN 43.28
- Support Level
- MIST $1.76
- CYBN $6.86
- Resistance Level
- MIST $1.96
- CYBN $8.00
- Average True Range (ATR)
- MIST 0.09
- CYBN 0.49
- MACD
- MIST -0.02
- CYBN -0.01
- Stochastic Oscillator
- MIST 13.79
- CYBN 10.48
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.